RxDoctor Payments Data

Diana Wooden, APRN

Family · Franklin, KYNPI 1912500604

Payments from drug & device makers

$5,441in general payments, 2019–2025

Across 160 payments — averaging $34.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$754
  • Axsome Therapeutics, Inc.$647
  • GSK$524
  • Astellas Pharma US Inc$368
  • Novo Nordisk$278
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$5,25197%
  • Education$1903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,441 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,919
Medicare patients
144
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol72$68,940
OzempicSemaglutide44$53,503
JardianceEmpagliflozin18$18,787
VascepaIcosapent Ethyl26$17,756
EntrestoSacubitril/Valsartan12$14,605
MounjaroTirzepatide14$14,350
EliquisApixaban11$13,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,427
LinzessLinaclotide12$12,126
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,715
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,733
Albuterol Sulfate HfaAlbuterol Sulfate64$1,963
Potassium Chloride18$1,100
Duloxetine Hcl20$1,041
Atorvastatin Calcium131$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,447$75,65483 claims
Novo NordiskOzempic$278$53,50344 claims
Boehringer IngelheimJardiance$33$18,78718 claims
Lilly USA, LLCMounjaro$66$14,35014 claims
PfizerEliquis$68$13,85511 claims
GSKTrelegy Ellipta$524$12,42720 claims
AbbVieLinzess$754$12,12612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Franklin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →